These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 8506382)
1. Prodrug activation via catalytic antibodies. Miyashita H; Karaki Y; Kikuchi M; Fujii I Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5337-40. PubMed ID: 8506382 [TBL] [Abstract][Full Text] [Related]
2. Thermodynamic and structural basis for transition-state stabilization in antibody-catalyzed hydrolysis. Oda M; Ito N; Tsumuraya T; Suzuki K; Sakakura M; Fujii I J Mol Biol; 2007 May; 369(1):198-209. PubMed ID: 17428500 [TBL] [Abstract][Full Text] [Related]
3. A structural basis for transition-state stabilization in antibody-catalyzed hydrolysis: crystal structures of an abzyme at 1. 8 A resolution. Kristensen O; Vassylyev DG; Tanaka F; Morikawa K; Fujii I J Mol Biol; 1998 Aug; 281(3):501-11. PubMed ID: 9698565 [TBL] [Abstract][Full Text] [Related]
4. Selective chemotherapeutic strategies using catalytic antibodies: a common pro-moiety for antibody-directed abzyme prodrug therapy. Kakinuma H; Fujii I; Nishi Y J Immunol Methods; 2002 Nov; 269(1-2):269-81. PubMed ID: 12379367 [TBL] [Abstract][Full Text] [Related]
5. Effects of substrate conformational strain on binding kinetics of catalytic antibodies. Oda M; Tsumuraya T; Fujii I Biophys Physicobiol; 2016; 13():135-138. PubMed ID: 27924267 [TBL] [Abstract][Full Text] [Related]
6. [Catalytic antibodies: generation of a new class of protein catalysts exploiting the immune system]. Fujii I Yakugaku Zasshi; 1996 Aug; 116(8):606-21. PubMed ID: 8831262 [TBL] [Abstract][Full Text] [Related]
7. Structural basis of the transition-state stabilization in antibody-catalyzed hydrolysis. Sakakura M; Takahashi H; Shimba N; Fujii I; Shimada I J Mol Biol; 2007 Mar; 367(1):133-47. PubMed ID: 17239396 [TBL] [Abstract][Full Text] [Related]
8. Site-directed mutagenesis of active site contact residues in a hydrolytic abzyme: evidence for an essential histidine involved in transition state stabilization. Miyashita H; Hara T; Tanimura R; Fukuyama S; Cagnon C; Kohara A; Fujii I J Mol Biol; 1997 Apr; 267(5):1247-57. PubMed ID: 9150409 [TBL] [Abstract][Full Text] [Related]
9. In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy. Shabat D; Lode HN; Pertl U; Reisfeld RA; Rader C; Lerner RA; Barbas CF Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7528-33. PubMed ID: 11404472 [TBL] [Abstract][Full Text] [Related]
10. [Catalytic antibody and its medical applications]. Fujii I; Iwabuchi Y Nihon Rinsho; 1995 Feb; 53(2):518-27. PubMed ID: 7699882 [TBL] [Abstract][Full Text] [Related]
11. Simple method for selecting catalytic monoclonal antibodies that exhibit turnover and specificity. Tawfik DS; Zemel RR; Arad-Yellin R; Green BS; Eshhar Z Biochemistry; 1990 Oct; 29(42):9916-21. PubMed ID: 2271630 [TBL] [Abstract][Full Text] [Related]
12. Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing. Wentworth P; Datta A; Blakey D; Boyle T; Partridge LJ; Blackburn GM Proc Natl Acad Sci U S A; 1996 Jan; 93(2):799-803. PubMed ID: 8570638 [TBL] [Abstract][Full Text] [Related]